HideChilds = False
SystemName =
 

Bioverativ is a global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders.

History of commitment to patients and science

Our Background

At Bioverativ, we are proud to carry forward a rich heritage of making a meaningful difference in the hemophilia community. 

We aim to honor our history of innovation by relentlessly pursuing the discovery and development of new medicines to address areas of serious need for people with hemophilia, sickle cell disease and other rare blood disorders.

Where We Came From

2017

Bioverativ is launched as an independent, publicly-traded, global biotechnology company

focused transforming the lives of people with hemophilia, sickle cell disease and other rare blood disorders.

2016

Biogen announces a planned spin-off of its hemophilia business

to form a separate company focused on the discovery, research, development and commercialization of therapies for hemophilia.

2014

ALPROLIX ®* is approved for treatment of hemophilia B in the United States, Canada and Japan.

ELOCTATE ®* is approved for treatment of hemophilia A in the United States, Canada and Japan.

2014

Biogen and Swedish Orphan Biovitrum (Sobi) announce pledge to donate up to 1 billion IUs of clotting factor to countries in the developing world.

2012

Biogen, in collaboration with the American Thrombosis and Hemostasis Network,

the National Hemophilia Foundation, and Bloodworks Northwest, launches free genetic testing for people with hemophilia A and B in the United States through My Life, Our Future campaign. The program is later expanded to include potential and confirmed carriers of the disorder.

2010

Biogen is the first to launch CoRes to support the community

2007

Biogen acquires Syntonix Pharmaceuticals

2003

Syntonix focuses on extended half-life hemophilia treatments.

1998

Syntonix Pharmaceuticals is founded, based on Harvard and Brandeis research.

1978

Biogen is founded by a group of accomplished scientists

to establish a new pharmaceutical company with an emphasis on breakthroughs in biology.

* Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts. During a temporary transition period, which includes time to allow Bioverativ to establish or transfer certain licenses related to ELOCTATE and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products.  Contact us with any questions.